Heart failure & cardiomyopathies
Real-Time Pulmonary Artery Pressure Monitoring in Heart Failure Patients: An Updated Cost-Effectiveness Analysis
Authors' conclusion
Our model suggests that CardioMEMS is likely to be cost-effective in the United Kingdom, at the currently considered thresholds of £20 000-30 000/QALY.
Study context
- Population
- Patients with persistent NYHA class III symptoms and ≥1 heart failure (HF) hospitalization within 12 months
- Comparison
- Pulmonary artery pressure (PAP)-guided HF therapy vs usual care
- Outcome
- Incremental cost per QALY gained (ICER)
- Follow-up
- 10 years
Methodological detailsMarkov model, 10-year time horizon, UK
- Markov model
- 10-year time horizon
- UK
Main finding
As reported in the abstract
10-year time horizon
Incremental cost
6337 £
PAP-guided
Incremental quality-adjusted life years (QALYs)
0.32 QALYs
PAP-guided
Usual care
- Cost
- £22 770
- QALYs
- 2.62
PAP-guided
- Cost
- £29 107
- QALYs
- 2.94
Cost
Usual care£22 770
PAP-guided£29 107
QALYs
Usual care2.62
PAP-guided2.94
- Incremental cost-effectiveness ratio (ICER) (incremental cost per QALY gained)
- £19 761/QALY
Further findings
ICER, scenario analyses (incl. real-world data)
- ICER range from dominant to
- £27 910/QALY
Probabilistic sensitivity analysis
- Probability CardioMEMS cost-effective at £30 000/QALY threshold
- 81.9%
Original publication
Real-Time Pulmonary Artery Pressure Monitoring in Heart Failure Patients: An Updated Cost-Effectiveness Analysis. ESC Heart Fail. Published 17 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →